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Background. Children with cerebral malaria (CM) have high rates of mortality and neurologic sequelae. Nitric
oxide (NO) metabolite levels in plasma and urine are reduced in CM.
Methods. This randomized trial assessed the efﬁcacy of inhaled NO versus nitrogen (N2) as an adjunctive treat-
ment for CM patients receiving intravenous artesunate. We hypothesized that patients treated with NO would have a
greater increase of the malaria biomarker, plasma angiopoietin-1 (Ang-1) after 48 hours of treatment.
Results. Ninety-two children with CM were randomized to receive either inhaled 80 part per million NO or N2
for 48 or more hours. Plasma Ang-1 levels increased in both treatment groups, but there was no difference between
the groups at 48 hours (P = not signiﬁcant [NS]). Plasma Ang-2 and cytokine levels (tumor necrosis factor-α, inter-
feron-γ, interleukin [IL]-1β, IL-6, IL-10, and monocyte chemoattractant protein-1) decreased between inclusion and
48 hours in both treatment groups, but there was no difference between the groups (P = NS). Nitric oxide metabolite
levels—blood methemoglobin and plasma nitrate—increased in patients treated with NO (both P < .05). Seven pa-
tients in the N2 group and 4 patients in the NO group died. Five patients in the N2 group and 6 in the NO group had
neurological sequelae at hospital discharge.
Conclusions. Breathing NO as an adjunctive treatment for CM for a minimum of 48 hours was safe, increased
blood methemoglobin and plasma nitrate levels, but did not result in a greater increase of plasma Ang-1 levels at 48
hours.
Keywords. cerebral malaria; methemoglobin; nitric oxide; Plasmodium falciparum.
Malaria kills more than half a million people per year,
and most are children in sub-Saharan Africa [1]. Cerebral
malaria (CM) is a catastrophic sequel of Plasmodium
falciparum malaria, with a mortality rate of approxi-
mately 20% [2], causing long-term neurological defects
in 10% to 24% of survivors [3, 4]. The most effective an-
tiparasitic therapy is intravenous (IV) artesunate, which
reduced mortality from 21% to 18% in African children
with CM [2]. Several adjunctive therapies have been
tested, but none have proven to be effective [5].
Nitric oxide (NO) is an intercellular messenger mol-
ecule synthesized by various cell types, including vascu-
lar endothelial cells. Nitric oxide is a vasodilator and
inhibits platelet aggregation, among numerous other ef-
fects [6]. Malaria severity was correlated with reduced
levels of biochemical markers of NO production [7].
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Physiological markers of reduced NO bioavailability—reduced
brachial artery postischemic vasodilation [8, 9] and increased
pulmonary arterial pressures [10]—were correlated with
increased cell-free hemoglobin levels in patients with severe
malaria, reﬂecting the NO-scavenging property of cell-free
hemoglobin.
Angiopoietin (Ang)-1 and its antagonist Ang-2 regulate en-
dothelial activation, and serum, plasma, or whole blood levels
have been studied as biomarkers of CM severity and disease
progression. Angiopoietin-1 levels were reduced and Ang-2 lev-
els were elevated in pediatric CM patients compared with
healthy children [11] and uncomplicated malaria patients [12,
13]. Signiﬁcantly elevated levels of Ang-2 were found in fatal
cases of CM and severe malaria [13].
Breathing low concentrations of NO gas reduces pulmonary
arterial pressures without producing systemic hypotension in
animal models and children [14, 15], and inhaled NO has
been safely used to treat persistent pulmonary hypertension
and other pulmonary disorders [16, 17] in neonates and infants
for over 20 years [18]. In Plasmodium berghei ANKA (PbA)-in-
fected mice (a murine CM model), breathing 40 or 80 parts per
million (ppm) of inhaled NO [19, 20] improved survival rates,
reduced plasma inﬂammatory markers, and increased plasma
Ang-1 levels. In other studies, inhaled NO reduced cerebral
injury in murine models of stroke [21, 22] and traumatic
brain injury [23].
Based on the well established clinical safety proﬁle of inhaled
NO and its efﬁcacy in experimental models of CM, we conduct-
ed an open-label randomized trial of breathing 80 ppm NO ver-
sus nitrogen (N2) as an adjunctive therapy to IV artesunate in
pediatric CM patients in Uganda. The primary endpoint was to
compare the increase of plasma Ang-1 levels over the ﬁrst 48
hours of treatment in patients breathing either NO or N2. Nitric
oxide delivery and safety were monitored and assessed by measur-
ing methemoglobin% (metHb%) and NO metabolites. Although
the study was too small to detect signiﬁcant changes, in-hospital
mortality, time to recovery from coma, and neurologic sequelae
for up to 6 months after discharge were also determined.
METHODS
Study Participants
We screened children aged 2 months to 12 years, weighing 5–
20 kg, at the tertiary care Mbarara Regional Referral Hospital
(MRRH) Pediatric Ward and the Holy Innocents Children’s
Hospital. We enrolled patients with a Blantyre coma score
(BCS) [24] <3/5 (for children aged <4 years) or Glasgow coma
score (GCS) <7/15 (for children aged 4–12 years), with a Plas-
modium infection conﬁrmed by thick blood smear (see Supple-
mentary Box 1 for additional inclusion and exclusion criteria).
Potential study patients were transferred to the research unit at
MRRH, and Ugandan research staff obtained informed consent
from ﬁrst-degree relatives, using materials written in English
and Runyankole (the local language). See the Supplement for
the full description of the institutions and supporting compa-
nies involved.
Study Design and Randomization
This was a randomized open-label, phase II clinical trial com-
paring breathing air or oxygen supplemented with inhaled NO
(80 ppm [by volume] in N2) or N2 in children with CM. Nitro-
gen has been used as an inert gas control in other trials of
inhaled NO [25]. After consent was obtained, we randomized
patients to either study arm using off-site computer-generated
random allocation. Sealed envelopes contained the patient
treatment designation and were opened after consent and
enrollment.
Survival was deﬁned as alive at the time of hospital discharge.
Patients were examined for neurological sequelae at the time of
discharge and at follow-up neurological assessments at 1, 3, and
6 months after discharge.
Study Oversight
This study was conducted in accordance with the ethical stan-
dards of the Helsinki Declaration of the World Medical Associ-
ation, and was approved by the institutional review boards of the
following institutions: Massachusetts General Hospital, Mbarara
University of Science and Technology, the Ugandan National
Council for Science and Technology, the Comité de Protection
des Personnes France, andMédecins Sans Frontières Internation-
al. The US Food and Drug Administration was notiﬁed, but an
Investigational New Drug approval was not required. The Ugan-
dan National Drug Authority approved the study. A data and
safety monitoring board was convened biannually, for a total of
3 meetings, to review the unblinded safety data based on serious
adverse events and mortality. The trial was registered under the
ClinicalTrials.gov: NCT01388842.
Study Procedures
The patient’s vital signs and coma score were assessed and
logged every 2 hours. Transcutaneous pulse oxygen saturation
(SpO2), methemoglobin (SpMET), hemoglobin levels, and
pulse rate were continuously monitored noninvasively with a
Radical 7 co-oximeter (Masimo, Irvine, CA). When elevated
transcutaneous SpMET levels were detected, blood metHb%
was measured with an Avox 4000 spectrophotometer (ITC,
Cambridge, MA) for conﬁrmation. Whole-blood hemoglobin
(g/dL) levels were measured with a Hemo Control Hemoglobin
Analyzer (EKF Diagnostics, Cardiff, UK). If the metHb% level
was 8.5% or greater, the inhaled gas dose was reduced by 50%
and then reduced by an additional 25% of the original dose if
the metHb% did not decrease below 8.5% within 1–2 hours.
Blood was sampled by venipuncture at enrollment (15 min-
utes before initiating study gas treatment, time 0) and at 12, 24,
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48, 72, and 120 hours after commencing treatment with study
gas. Blood-based measurements included the following: hemo-
globin, complete blood count, parasite smears, and plasma lev-
els of creatinine, lactate, Ang-1 and Ang-2, cytokines (tumor
necrosis factor [TNF]-α, interferon [IFN]-γ, interleukin [IL]-
1β, IL-6, IL-10, and monocyte chemoattractant protein
[MCP]-1), S100b, and NO metabolites (nitrate, nitrite, N-nitro-
samines [RNNO], S-nitrosothiols [RSNO]). A total of 10 mL of
blood was sampled for research analyses from each patient over
the 5-day study period. See the Supplement for a description of
speciﬁc laboratory procedures.
Gas Administration
Study gas was delivered to the patient via a nasal cannula with a
metered dosing apparatus speciﬁcally developed for investiga-
tional use (INOPulseTM, Ikaria, Inc., NJ) [25]. The gas volume,
and thus the gas dose to be delivered, was determined with a
nomogram, incorporating the child’s weight (to estimate tidal
volume) and respiratory rate (see the Supplement for further
description). Because the INOPulse was limited to 10 mL of
gas injection per breath, to avoid under-dosing NO gas we
were restricted to enrolling children weighing less than 20 kg.
Enrolled patients received study gas for a targeted minimum
of 48 hours and a maximum of 120 hours. All patients with a
SpO2≤ 94% were given supplemental oxygen by facemask.
If, during the course of treatment, a patient’s respiratory rate
(and therefore alveolar minute ventilation) changed, his/her IN-
OPulse gas dose was adjusted using the nomogram. If the patient
regained full consciousness (BCS 5/5 or GCS 15/15) and had
received treatment gas for greater than 48 hours, or if the patient
completed 120 hours of gas treatment regardless of clinical status,
the treatment gas was reduced by 50% each hour until turned off.
Concomitant Treatment
Enrolled patients received IV artesunate per protocol for at least
48 hours and up to 5 days. Patients able to take oral medications
were transitioned to a 3-day course of artemether/lumefantrine
(Coartem; Novartis Pharma, Switzerland) after 48 hours of IV
artesunate treatment (see the Supplement for additional treat-
ments and interventions).
Study Endpoints
The primary study endpoint was the increase of plasma Ang-1 lev-
els at 48 hours. The secondary laboratory endpoints included re-
duction in plasma Ang-2, the Ang-2/Ang-1 ratio, selected plasma
cytokine levels and creatinine, and blood lactate. The Ang-2/Ang-
1 ratio was calculated for each patient, and the mean of these ratios
is reported. Additional secondary endpoints included mortality
during hospitalization, time taken to recover from coma, and neu-
rological sequelae occurring up to 6 months after discharge. We
evaluated the safety of NO delivery, and we monitored metHb%
and NO metabolites to conﬁrm inhalation and uptake of NO.
Statistical Analysis
We compared proportions with a χ² or Fisher’s exact test with
2-sided P values. We assessed data within groups using a 2-
tailed paired t test or Wilcoxon matched-pairs signed-rank
test, and we assessed data between groups using a Mann–
Whitney U test. Data between the N2 and NO treatment
Figure 1. Screening, enrollment, and randomization ﬂow diagram. Abbreviations: metHb%, percentage of methemoglobin; N2, nitrogen; NO, nitric oxide.
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cohorts, and within treatment cohorts at hours 0 and 48, were
compared from patients who received gas for at least 48 hours
and those for whom we had paired data. We compared survival
and time to coma recovery curves using Kaplan–Meier curves
and log-rank test (or Wilcoxon Breslow when appropriate). Sta-
tistics and graphs were generated with Stata software (Release
13, StataCorp.) and GraphPad Prism 6 (GraphPad Software,
Inc.). The level of statistical signiﬁcance was set at 0.05. All re-
sults are displayed as mean ± standard deviation (SD). The tar-
get census for the study was 92 patients (see the Supplement for
a description of how the study was powered).
RESULTS
Baseline Characteristics and Clinical Course
Between September 2011 and July 2013, 360 patients with a
clinical diagnosis of CM were screened for eligibility. Ninety-
two patients were included in the study, and their parent or
guardian gave informed consent to enter the trial. Forty-six pa-
tients were randomly assigned to each treatment group. Eight
patients enrolled in the study were not included in the per-
protocol analysis: 3 patients in the N2 group and 5 patients in
the NO group (Figure 1). There was no difference in baseline
characteristics or laboratory values between enrolled NO- and
N2-treated patients (Table 1).
There was no difference in the duration of treatment with
study gas among patients treated ≥48 hours: 60.1 ± 23.3 hours
and 63.9 ± 23.9 hours for N2- and NO-treated patients, respec-
tively (P = not signiﬁcant [NS]). For patients receiving NO, the
mean inhaled dose for the initial 48 hours of therapy was
0.55 ± 0.12 mg/kg per hour (N = 39) (Figure 2A).
Seventy-nine patients (38 N2, 41 NO) returned for examina-
tion at 1 month after discharge, 76 patients (37 N2, 39 NO)
returned at 3 months, and 75 patients (36 N2, 39 NO) returned
at 6 months. The trial ended when the ﬁnal enrolled patient
completed the 6-month follow-up visit, in February 2014.
Primary and Secondary Endpoints and Outcomes
Table 2 shows the plasma Ang-1 and Ang-2 levels and the Ang-
2/Ang-1 ratio at baseline (hour 0) and 48 hours later (hour 48).
Table 1. Baseline Clinical and Laboratory Data of Patients Enrolled
in the Treatment Groups*
Characteristic N2 (N = 46) NO (N = 46)
Female sex, no. (%) 24 (52.2%) 19 (41.3%)
Age, month 33.5 ± 22.4 42.4 ± 23.3
Age <48 month, no. (%) 36 (78.3%) 29 (63.0%)
Age ≥48 month, no. (%) 10 (21.7%) 17 (37.0%)
Weight, kg 11.6 ± 3.7 12.7 ± 3.3
Temperature, °C 38.1 ± 1.1 37.9 ± 1.3
SpO2, % 97.8 ± 4.2 98.2 ± 2.0
Blood metHb, % (N) 0.6 ± 0.1 (37) 0.6 ± 0.1 (34)
Heart rate, BPM 147 ± 23 143 ± 25
Respiratory rate, BPM 37 ± 11 38 ± 13
Blood pressure, mmHg
Systolic (N) 95 ± 11 (45) 98 ± 11 (44)
Diastolic (N) 53 ± 12 (45) 55 ± 10 (44)
Blantyre coma score (N) 1.3 ± 0.7 (36) 1.2 ± 0.8 (29)
Glasgow coma score (N) 5.6 ± 0.7 (10) 5.9 ± 0.5 (17)
History of seizures prior to
admission, no. (%)
40 (87.0) 38 (82.6)
Malaria retinopathy (any finding),
no. (%)
27 (58.7) 23 (50.0)
WBC, no. ×103/µL 13.5 ± 7.1 16.8 ± 11.4
Hematocrit, % 23.3 ± 5.3 25.9 ± 6.7
Hemoglobin, g/dL 7.8 ± 2.1 8.7 ± 2.2
Platelets, no. ×103/µL 93 ± 83 78 ± 68
Parasites, trophozoites,
Parasite no. ×103/µL (N)
61 ± 100 56 ± 130
Abbreviations: BPM, beats perminute;metHb,methemoglobin; N2, nitrogen; NO,
nitric oxide; NS, not significant; SD, standard deviation; SpO2, transcutaneous
pulse oxygen saturation; WBC, white blood cells.
* All data are mean ± SD. P =NS comparing N2 to NO.
Figure 2. (A) Kaplan-Meier curves comparing survival in pediatric patients
with cerebral malaria (CM) treated with nitrogen (N2) or nitric oxide (NO).
P = not signiﬁcant (NS). (B) Kaplan-Meier curves for resolution of coma
in pediatric patients with CM, N2 vs NO; resolution of coma is deﬁned as
Blantyre coma score ≥ 3 or Glasgow coma score of ≥7; (N2 N = 39, NO
N = 41). P = NS. Abbreviations: INO, inhaled NO; metHb%, percentage of
methemoglobin.
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There was an increase of plasma Ang-1 levels in the NO group
over 48 hours (P = .016), whereas there was no statistically sig-
niﬁcant increase in the N2 group (P = .085). However, there was
no difference in the change from baseline of plasma Ang-1 levels
between the treatment groups. There was a signiﬁcant decrease
in plasma Ang-2 levels and the Ang-2/Ang-1 ratios over the 48
hours of treatment in both groups (P < .0001). There was no dif-
ference in (1) plasma Ang-2 or (2) the Ang-2/Ang-1 ratio be-
tween the treatment groups at either 0 or 48 hours.
In both groups, plasma TNF-α, IL-1β, and IL-6 levels were
less at 48 hours than upon enrollment (Table 2), but there
was no difference between the treatment groups at 0 or 48
hours (P = NS). Similar ﬁndings were obtained for plasma levels
of IFN-γ, IL-10, and MCP-1 (Supplementary Table 1). Plasma
levels of S100b, a biomarker of neural tissue injury [26], de-
creased after 48 hours in both treatment groups (Table 2),
with no difference between treatment groups (P = NS).
There was no difference in the time to clear circulating par-
asites between the N2 (N = 40) and NO (N = 43) treatment
groups: 42.9 ± 26.2 and 40.7 ± 26.1 hours, respectively. More-
over, there was no signiﬁcant difference in (1) the rate children
became afebrile (<38°C) or (2) the change of blood creatinine or
lactate levels over 48 hours between the gas treatment groups
(see Supplementary Table 2 for creatinine and lactate levels).
There were no clinically signiﬁcant differences in heart rate,
systolic blood pressure, or SpO2 after initiating treatment in pa-
tients receiving NO versus N2. In addition, the number of pa-
tients affected by severe adverse events (SAEs), or any adverse
events (AEs), including cardiopulmonary or respiratory com-
plications, was similar in the 2 treatment groups.
Eleven (12.0%) of 92 enrolled CM patients died while in the
hospital (Table 3), 7 of whom were treated with N2 (15.2%) and
4 of whom were treated with NO (8.7%). Of the patients who
were living at the time of hospital discharge (39 N2, 42 NO),
Table 2. Primary and Secondary Laboratory Outcomes*
Angiopoietins Interval N2 (N = 42) NO (N = 39) Intragroup P Value Intergroup P Value
Ang-1, pg/dL Hour 0 2049 ± 2392 1733 ± 2485 .73
Hour 48 3235 ± 3516 2837 ± 3152 N2 = 0.085
NO= 0.016
.81
Ang-2, pg/dL Hour 0 16235 ± 16216 14440 ± 12202 .41
Hour 48 5901 ± 8424 4801 ± 4831 N2 < 0.0001
NO< 0.0001
.78
Ang-2/Ang-1 Ratio Hour 0 19.62 ± 24.29 35.35 ± 119.10 .94
Hour 48 7.80 ± 20.58 5.71 ± 11.35 N2 < 0.0001
NO< 0.0001
.96
Cytokines N2 (N = 40) NO (N = 40)
TNF-α, pg/mL Hour 0 0.297 ± 0.495 0.311 ± 0.600 .90
Hour 48 0.095 ± 0.410 0.008 ± 0.026 N2 = 0.0005
NO< 0.0001
.99
IL-1β, pg/mL Hour 0 0.359 ± 0.631 0.508 ± 0.910 .74
Hour 48 0.151 ± 0.649 0.024 ± 0.074 N2 = 0.007
NO< 0.0001
.93
IL-6, pg/mL Hour 0 84.63 ± 108.60 99.19 ± 122.30 .88
Hour 48 8.04 ± 27.56 13.46 ± 60.56 N2 < 0.0001
NO< 0.0001
.70
S100b N2 (N = 37) NO (N = 38)
S100b, pg/mL Hour 0 931.2 ± 813.7 922.7 ± 861.5 .80
Hour 48 283.8 ± 400.4 318.8 ± 477.1 N2 < 0.0001
NO= 0.0001
.85
Abbreviations: Ang, angiopoietin; IL, interleukin; N2, nitrogen; NO, nitric oxide; SD, standard deviation; TNF, tumor necrosis factor.
* Plasma levels of Ang-1, Ang-2, cytokines, and S100b, as well as the ratio of plasma Ang-2 levels to plasma Ang-1 levels on enrollment and after 48 hours. All data
are mean ± SD.
Table 3. Secondary Clinical Outcomes*
N2 NO
Died before 7 days after
enrollment
7 of 46 (15.2%) 4 of 46 (8.7%)
Survived 1 month after
discharge
39 of 46 (84.8%) 42 of 46 (91.3%)
Neurological sequelae
in 1-month survivors
5 of 39 (12.8%) 6 of 42 (14.3%)
Full recovery in 1-month
survivors
34 of 39 (87.2%) 36 of 42 (85.7%)
Abbreviations: N2, nitrogen; NO, nitric oxide; NS, not significant.
* All data are presented as number and percentage of patients in each
treatment group. P =NS comparing N2 to NO.
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5 of the patients treated with N2 (12.8%) and 6 of the patients
treated with NO (14.3%) exhibited neurological sequelae at the
1-month follow-up visit. Neurological sequelae included ataxia,
hemiplegia, hypotonia, seizures, speech dysfunction, and/or be-
havioral disorders. Of the 11 patients with neurological sequelae
at the time of discharge, 3 patients (1 N2, 2 NO) resolved their
neurological sequelae by the 6-month follow-up visit. Figure 3A
shows the Kaplan-Meier survival curve for the 5 days after ran-
domization into the study for patients treated with either N2 or
NO (P = NS). There was no difference in the rate of recovery
from coma between the NO and N2 treatment groups (P =
NS; Figure 3B), with the duration of coma of 48.1 ± 58.2
hours and 55.8 ± 50.1 hours for the N2 and NO treatment
groups, respectively.
Focusing only on those patients with evidence of malarial ret-
inopathy (N = 27, 58.7% N2 group; N = 23, 50.0% NO group),
we observed that there was no difference in the change in (1)
Ang-1, Ang-2, Ang-2/Ang-1 ratio between 0 and 48 hours or
(2) the survival rate between patients receiving NO or N2.
Nitric Oxide Metabolic Products and Effects
Blood metHb, nitrate, nitrite, RSNO, and RNNO are NO reac-
tion products. Before breathing NO, baseline blood metHb%
levels in the N2 and NO groups were 0.6 ± 0.1% (N = 37) and
0.6 ± 0.1% (N = 34), respectively (P = NS) (Figure 2B). In the
NO group, blood metHb% levels increased to 4.1 ± 0.4%
(N = 33) at 12 hours, 3.2 ± 0.3% (N = 33) at 24 hours, 2.4 ±
0.3% (N = 33) at 48 hours, and 1.4 ± 0.4% (N = 32) at 72 hours
(P < .0001 at 12, 24, and 48 hours, and P = .03 at hour 72), when
compared with patients breathing N2, in whom levels of blood
metHb% did not change. The decrease in metHb% levels between
24 and 72 hours reﬂects the reduction or cessation of NO admin-
istration, because coma was reversed during recovery. Of note, 6
NO patients transiently developed metHb% levels ≥10%, and a
reduction of the inhaled NO dose per protocol led to a rapid de-
cline in metHb% levels in each patient within 2 hours.
There was no difference of baseline nitrate levels in patients
treated with N2 or NO (P = NS) (Figure 2C). Nitrate levels
decreased in the N2-treated group over 48 hours, from
47.7 ± 21.1 to 29.5 ± 22.8 μM (P < .05). In contrast, nitrate levels
increased over 48 hours with NO treatment from 56.7 ± 28.2 to
94.7 ± 52.5 μM (P < .05). Plasma nitrate levels at 48 hours were
markedly greater in patients breathing NO versus N2 (P < .01).
After discontinuation of NO breathing, nitrate levels returned
to baseline by 120 hours. Nitrite levels (Figure 2D) did not
change signiﬁcantly from hour 0 to 48 in either group but
decreased from 48 hours to 120 hours in NO-treated patients
(P < .05). The nitrite levels in the N2- and NO-treated patients
differed at 120 hours (P < .05). Plasma RSNO and RNNO
levels were not signiﬁcantly different between the treatment
groups at hours 0, 48, and 120 of treatment (Supplementary
Table 2).
Figure 3. (A) Delivered dose of nitric oxide (NO) over 120 hours (mg/kg per hour); (B) blood methemoglobin (percentage of methemoglobin [metHb %]) in
patients treated with nitrogen (N2) and NO; (C) Plasma nitrate (μM) levels; and (D) plasma nitrite (μM) levels in patients treated with N2 or NO. *P < .001
and **P < .05, NO versus N2. All data mean ± standard deviation.
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DISCUSSION
This randomized trial compared breathing 80 ppm NO versus
N2 as an in-hospital adjunctive therapy for 92 comatose pediat-
ric patients with CM. There was no signiﬁcant difference of
plasma Ang-1, Ang-2, or cytokine levels between the groups
after 48 hours of treatment (Table 2).
Nitric oxide proved to be effective in murine CM models,
wherein PbA-infected C57BL/6 mice treated with a systemic
NO donor (dipropylenetriamine NONOate), or breathing 40
ppm NO, had improved survival [19]. Prophylactic treatment
with 80 ppm NO in the same model, with and without antima-
larial therapy, resulted in a reduced mortality rate, a greater in-
crease of plasma Ang-1 levels, reduced brain mRNA copy
numbers of the ratio of Ang-2/Ang-1, and reduced plasma lev-
els of IFN-γ, TNF, and MCP-1 [20].
In this small clinical trial, we found an overall mortality rate
of 12%, with fewer patients dying breathing NO; however, NO
treatment did not signiﬁcantly reduce the mortality rate. The
overall mortality was less than the 18% reported in a recent mul-
ticenter study of 5425 children with severe malaria (of whom
1825 had CM) treated with IV artesunate [2]. The overall inci-
dence rate of neurological sequelae in our study was 12%, which
is similar to the 10%–25% rate reported in sub-Saharan Africa
[3, 4]. We believe NO treatment to be safe because the mortality
rate in our study was low, breathing NO did not increase the
incidence of neurological sequelae, mean methemoglobin levels
remained low (4.1% ± 0.4%), and the number of patients affect-
ed by SAEs and AEs were similar in both groups.
Plasma S100b, a biomarker of injury to astrocytes, oligoden-
drocytes, and other neural cell types, is increased in patients
after traumatic brain injury and cardiac arrest [26–28]. Elevated
S100b levels have been measured in adult and pediatric CM pa-
tients with seizures, but this was only investigated using cere-
brospinal ﬂuid [29, 30]. We measured plasma S100b levels in
our CM patients, and, although we found no signiﬁcant differ-
ence in the reduction of the levels between the treatment groups
over 48 hours (Table 2), plasma S100b may be useful as a tool
for assessing the level of central nervous system injury in future
studies involving CM patients.
We delivered NO or N2 with the INOPulse, a gas injector that
was triggered on inspiration. Even though it was not possible to
measure the precise NO concentration in the trachea of children
receiving NO gas with the INOPulse, we conﬁrmed that NO
was inhaled by detecting elevated levels of blood metHb%
and plasma NO metabolites (Figure 2B and C). Similar obser-
vations were reported by Gladwin et al [25], among adult sickle
cell patients breathing 40 or 80 ppm NO using the INOPulse.
We measured plasma NO metabolites in an effort to better
understand their changes in CM patients breathing NO, and
we observed increased plasma nitrate levels in the NO arm
and a reduction of nitrate levels in the N2 arm after 48 hours
of treatment (Figure 2C). After inhalation, NO has an extremely
short half-life with 97% rapidly converted to nitrate and the re-
mainder to stable adducts (S-nitrosylated proteins [eg, S-nitro-
sothiols or N-nitrosamines], nitrosyl-hemeproteins, and
nitrite), which can release NO in systemic vascular beds by
various mechanisms [31, 32]. Studies have shown beneﬁcial
extrapulmonary effects of inhaled NO in humans, including re-
duced platelet aggregation [33], reduced myocardial injury after
cardiopulmonary bypass [34], increased renal blood ﬂow [35],
enhanced liver allograft function in liver transplant recipients
[36], and reduced inﬂammation in lower extremity ischemia-
reperfusion from tourniquet use [37].
Despite the possible vasodilatory and anti-inﬂammatory ben-
eﬁts of inhaled NO described above, including the positive out-
comes of NO trials in murine models of CM [11, 12],we did not
ﬁnd a signiﬁcant difference in the change of plasma Ang-1 or
Ang-2 levels after 48 hours of inhaled NO treatment. Plasma
angiopoietin levels have been correlated to the severity of illness
in severe malaria and CM patients [11, 12]. In the future, it may
be valuable to focus the administration of inhaled NO upon CM
patients with laboratory evidence of NO scavenging and pulmo-
nary or systemic vasoconstriction. We would suggest studying
the subset of CM patients with elevated levels of plasma cell-
free hemoglobin and therefore increased NO scavenging and
consumption [38]. This subset has shown evidence of increased
right heart/pulmonary pressures on echocardiogram [10]. It is
also possible that this subset of patients suffer from increased
cerebrovascular resistance with reduced cerebral blood ﬂow.
Breathing NO oxidizes cell-free hemoglobin to metHb, thereby
reducing its ability to scavenge intrinsic NO [39]. Inhaling NO
may have greater clinical efﬁcacy in this subgroup of patients.
CONCLUSIONS
Treatment with NO did not signiﬁcantly increase plasma Ang-1
levels at 48 hours compared with patients treated with N2. This
small trial could not demonstrate a reduction of mortality or
neurological impairment in children treated with NO. Seven pa-
tients in the N2 group and 4 patients in the NO group died. A
larger trial, utilizing measurements of cell-free hemoglobin and
right heart pressures to assess pulmonary vasoconstriction,
would be required to learn whether breathing NO could lead
to improved survival rates in this subgroup of malaria patients.
Supplementary Material
Supplementary material is available online at Open Forum Infectious Diseases
(http://OpenForumInfectiousDiseases.oxfordjournals.org/).
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Supplementary Material 
 
Box S1.  Inclusion and Exclusion Criteria 
Box 1. 
The inclusion criteria for this study were: 
• Age 2 months - 12 years, and weight 5 – 20 kg 
• Positive malaria antigen test and confirmed by parasites observed on thick blood 
smear  
• Cerebral malaria with Blantyre coma score < 3 for children aged < 4 years, or 
Glasgow coma score < 7 for children aged 4 – 12 years 
• Informed consent from a parent or guardian 
Exclusion criteria for this study were: 
• Another cause of coma (toxin ingestion or pre-existing severe neurological 
disease) 
• Evidence and/or history of pre-existing brain injury and neurologic impairment 
• Impending respiratory failure: patient requiring bag mask ventilation 
• Clinical evidence of a coagulopathy: persistent bleeding from nose or mouth or IV 
sites  
• Severe chronic malnutrition with marasmus or Kwashiorkor edema and/or a 
weight-for-height Z-score of ≤ -3 SD (WHO standards) 
• Advanced AIDS (wasting, super-infection, cardiomyopathy, and neuropathy 
secondary to HIV, as defined by WHO clinical stage 4) 
  
Laboratory Procedures  
All laboratory analytical procedures were carried out in a blinded fashion. Serum 
electrolyte levels were determined at the bedside with an iStat (i-STAT, Abbott 
Laboratories, Abbott Park, IL, USA). AST and ALT were determined in the laboratory 
with a Cobas Mira biochemistry spectrophotometry analyzer (Roche Diagnostics, 
Indianapolis, IN, USA). CBCs were analyzed with an ABX Pentra 60 cytochemistry 
analyzer (Horiba, Kyoto, Japan). Plasma from blood samples was collected in EDTA 
and separated by centrifugation at 1730g for 5 minutes at room temperature and stored 
at −80°C.  
 Patients were initially tested for the presence of parasites with the SD Bioline 
Malaria Ag P.f/Pan (Standard Diagnostics Ref 05FK60, Inc., Suwon City, Republic of 
Korea) rapid diagnostic test. The presence of parasites was then confirmed by a thick 
smear and patients were considered negative if no parasites were detected over 100 
fields. Parasite species was confirmed by thin blood smear, and counts were 
determined by thick smear, after staining with 10% Giemsa, and asexual parasites were 
counted over 200 – 500 leukocytes (depending on parasite density) and converted to 
parasites/μL of blood by assuming a blood leukocyte concentration of 8000/μL whole 
blood. 
Plasma Ang-1 and Ang-2 levels were determined using ELISA assays (R&D 
Systems, DANG10 and DANG20 kits, Minneapolis, MN, USA). Plasma TNF-α, IFN-γ, 
IL-1β, IL-6, and IL-10 levels were measured using the BD multiplexed enhanced 
sensitivity bead system (Becton Dickinson, Waltham, MA, USA). Plasma S100B levels 
were measured at MGH using a human S100B ELISA assay (BioVendor, Heidelberg, 
Germany). Results for angiopoietin, cytokine, and S100B levels are reported if the 
patient received study drug for ≥ 48 hours, and if there were paired data points at 
baseline and 48h of treatment.   
 Plasma levels of NO metabolites (nitrate, nitrite, RSNO, and RNNO) from 14 
patients receiving NO and 18 breathing N2 were measured using high-pressure liquid 
chromatography and gas-phase chemiluminescence techniques, as described 
previously [1]. 
  
GAS DELIVERY DETAILS USING THE INOPulse™ 
The INOPulse™ monitors the inspiratory pressure of the patient’s breath, and injects a 
prescribed volume (“pulse”) of study gas during the first half of each inhalation, via the 
nasal cannula. Administering gas via the INOPulse™ minimized both the volume of NO 
or N2 gas required for the study and the time NO contacted oxygen, thus reducing 
formation of nitrogen dioxide. As described in the text, the gas volume to be delivered, 
and, thus, the dose of NO or N2 was determined with a nomogram, incorporating the 
child’s weight (to estimate tidal volume) and respiratory rate. When the child inhaled, the 
INOPulse™ injected 800 ppm of NO into the nasal cannula. We estimate that a ten-fold 
dilution of the injected gas with alveolar gas volume resulted in an alveolar NO gas 
concentration of approximately 80 ppm. The delivered NO dose per hour (mg/kg per hr) 
was calculated by multiplying the estimated inhaled concentration by the estimated 
minute ventilation and divided by the patient weight in kilograms.   
  
Concomitant Treatment And Interventions 
A blood and urine culture, and lumbar puncture were obtained whenever possible from 
all patients. Repeat urine, blood, and/or cerebral spinal fluid cultures were obtained if 
there was evidence of bacterial infection.  
Fundoscopy was attempted on patients within the first 24 hours of treatment. 
Cycloplegia was obtained with myadriaticum drops (tropicamide 0.5%) with 
phenylephrine 5% within the first 24 hours of treatment. Selected aspects of malarial 
retinopathy were recorded when present, including: hemorrhages, papilledema, macular 
and peripheral retinal whitening, and vascular changes. 
Blood transfusions (10 mL/kg of packed red blood cells or 20 mL/kg of whole 
blood) were given whenever hemoglobin was ≤ 7 g/dL. Children were given ascorbic 
acid (5 – 10 mg/kg/day) via mouth or nasogastric tube for 5 days [2]. Patients received 
enteral feedings via a nasogastric tube, when appropriate. Anti-seizure medications, 
antipyretics, antibiotics, and fluid boluses were given at the discretion of the clinician.  
  
How The Study Was Powered 
Using previous data on Ang-1 on children with CM, reported in the literature, a 
sample size of 92 (46 in each arm) was needed to provide adequate power (80%) with a 
2 sided test and alpha of 5% to detect the expected difference in Ang-1 between the two 
arms, using the Wilcoxon (Mann-Whitney) rank-sum test (nQuery Advisor 6.01).  
 
  
For Figure 1. Detailed reasons for excluding patients from analyses 
N2: 
Three patients assigned to the N2 breathing arm were not treated per protocol: all 3 died 
prior to 24 hours, including one that was randomized but died just prior to the initiation 
of treatment.   
NO: 
Five patients assigned to the NO breathing arm were not treated per protocol: 1 patient 
died prior to 24 hours; 2 patients were removed from treatment prior to 24 hours for high 
metHb% levels; and 1 was enrolled and randomized at the same time she developed a 
GCS of 7/15, too high for inclusion, and thus was removed from analysis.  
Supplement Table S1. Plasma IFN-γ, IL-10, and MCP-1 Levels At Enrollment and After 
48 Hours. All data mean±SD.   
Cytokines Interval N2 (N=40) NO (N=40) 
Intra-group p-
value 
Inter-
group p-
value 
IFN-γ, pg/mL 
Hr 0 8.02 ± 20.85 9.15 ± 19.64  0.20 
Hr 48 1.01 ± 4.17 0.92 ± 3.02 N2 0.0129;  NO < 0.0001 0.65 
IL-10, pg/mL 
Hr 0 162.2 ± 209.7 153.6 ± 183.1  0.77 
Hr 48 8.8 ± 12.1 9.7 ± 14.1 N2 < 0.0001;  NO < 0.0001 0.94 
  N2 (N=37) NO (N=37)   
MCP-1, 
pg/mL 
Hr 0 133.8 ± 211.6 215.9 ± 535.1  0.36 
Hr 48 25.3 ± 34.7 49.6 ± 68.8 N2 0.0039;  NO 0.038 0.024 
 
  
Supplement Table S2. Secondary Laboratory Outcomes. Plasma creatinine, blood 
lactate, and plasma RNNO and RSNO levels. *Absence of paired data. All data 
mean±SD.   
Lab values Interval N2 (N) NO (N) 
Intra-group p-
value from 
baseline, Hr 0 
Inter-
group p-
value 
Creatinine, mg/dL 
Hr 0 1.09 ± 0.92 (38) 
1.18 ± 1.10 
(36)  0.79 
Hr 48 1.54 ± 3.00 (37) 
0.80 ± 0.93 
(36) 
N2 = 0.139; 
NO<0.0001 0.42 
Day 5 0.71 ± 0.84 (33) 
0.83 ± 1.33 
(34) 
N2 = 0.0058;  
NO = 0.0037 0.83 
Lactate, mg/dL 
Hr 0 24.23 ± 12.68 (42) 
24.01 ± 
17.02 (41)  0.64 
Hr 48 16.84 ± 7.18 (42) 
17.62 ± 
11.66 (41) 
N2 = 0.0049;  
NO = 0.029 0.56 
Day 5 23.92 ± 9.08 (36) 
20.96 ± 7.91 
(39) 
N2 = 0.846;  
NO = 0.5572 0.19 
RNNO, nM 
Hr 0 29.4 ± 21.1 (4) 
32.0 ± 22.9 
(6)  0.86 
Hr 48 15.1 ± 8.0 (4) 
15.1 ± 9.3 
(5) N/A* 1.0 
Day 5 14.1 ± 5.7 (5) 
10.3 ± 2.6 
(5) N/A* 0.21 
RSNO, nM 
Hr 0 12.5 ± 8.3 (4) 
20.1 ± 23.0 
(6)  0.55 
Hr 48 9.1 ± 4.9 (4) 10.3 ± 7.4 (5) N/A* 0.79 
Day 5 6.6 ± 7.3 (5) 22.8 ± 20.3 (5) N/A* 0.13 
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